These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review. Stamenović J; Živadinović B; Đurić V J Chin Med Assoc; 2024 Aug; ():. PubMed ID: 39118220 [TBL] [Abstract][Full Text] [Related]
31. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
32. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905 [TBL] [Abstract][Full Text] [Related]
33. Hallucinations and psychosis in Parkinson's disease. Rabey JM Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547 [TBL] [Abstract][Full Text] [Related]
34. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. Williams-Gray CH; Foltynie T; Lewis SJ; Barker RA CNS Drugs; 2006; 20(6):477-505. PubMed ID: 16734499 [TBL] [Abstract][Full Text] [Related]
35. Neuropsychiatric features of Parkinson's disease in the era prior to the use of dopaminergic therapies. Zhang C; Reeves S; David AS; Costello H; Rogers J Cogn Neuropsychiatry; 2023 Jul; 28(4):243-252. PubMed ID: 37170593 [TBL] [Abstract][Full Text] [Related]
36. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates]. Kashihara K; Ohno M; Katsu Y Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992 [TBL] [Abstract][Full Text] [Related]
37. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease. Müller T Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823 [TBL] [Abstract][Full Text] [Related]
38. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
39. Using Telemedicine to Assess and Manage Psychosis Among Outpatients with Neurodegenerative Disease. Chepke C; Shaughnessy LW; Brunton S; Farmer JG; Rosenzweig AS; Grossberg GT; Wright WL Int J Gen Med; 2021; 14():10271-10280. PubMed ID: 34992442 [TBL] [Abstract][Full Text] [Related]
40. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]